A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2

Exclusion Criteria

• •Treatment with systemic steroids for at least 3 weeks within past 6 months
• •Patients with a known pancreatic exocrine insufficiency due to non-diabetic diseases, e.g., chronic pancreatitis, pancreatectomy, cystic fibrosis, celiac disease, shwachman-diamond syndrome, gastrectomy, etc.
• •Any type of malignancy involving digestive tract in the last 5 years
• •Any type of gastrointestinal surgery (except appendectomy and gallbladder resection)
• •Short bowel syndrome
• •Hemochromatosis
• •Known late onset autoimmune diabetes in the adult
• •Any history of drug abuse including alcohol
• •Positive urine pregnancy test; lactation; females of child-bearing potential who are not using either an oral hormonal contraceptive or an intrauterine device
• •Hypersensitivity to the active substance or to any of the excipients
• •Intake of an experimental drug within 4 weeks prior to entry into this study
• •Suspected non-compliance or non-cooperation
• •History of human immunodeficiency virus (HIV) infection